Cart
sales@molnova.com
MA-0204
CAS No. 2095128-17-7
MA-0204( —— )
Catalog No. M23943 CAS No. 2095128-17-7
MA-0204 is a highly selective and orally available peroxisome proliferator-activated receptor δ (PPARδ) modulator.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 282 | In Stock |
|
| 10MG | 475 | In Stock |
|
| 25MG | 773 | In Stock |
|
| 50MG | 1071 | In Stock |
|
| 100MG | 1422 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMA-0204
-
NoteResearch use only, not for human use.
-
Brief DescriptionMA-0204 is a highly selective and orally available peroxisome proliferator-activated receptor δ (PPARδ) modulator.
-
DescriptionMA-0204 is a highly selective and orally available peroxisome proliferator-activated receptor δ (PPARδ) modulator (EC50s: 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ, respectively). It is a potential treatment for Duchene Muscular Dystrophy (DMD).
-
In VitroMA-0204 is >10,000-fold selective for activation of PPARδ over PPARα and PPARγ receptors. MA-0204 exhibits high protein binding to mouse plasma, good permeability and low potential for efflux. C.MA-0204 (1.2-12 nM) improves fatty acid oxidation in DMD patient muscle myoblasts mice.MA-0204 (0.04-40 nM) engages target gene expression in DMD patient muscle myoblasts.
-
In VivoPPARδ (30, 100 mg/kg) increases target gene transcription in the muscle.
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetPPAR
-
RecptorPPARδ
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2095128-17-7
-
Formula Weight476.49
-
Molecular FormulaC25H27F3N2O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:40 mg/mL (83.95 mM; Need ultrasonic)
-
SMILESC[C@H](CCCOc1c(Cn2c(-c(cc3)ccc3OC(F)(F)F)ncc2C)cccc1)CC(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Lagu B, et al. Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD). ACS Med Chem Lett. 2018 Jul 31;9(9):935-940.
molnova catalog
related products
-
Rosiglitazone
A potent and selective PPARγ agonist that binds to the PPARγ ligand-binding domain with a Kd of 40 nM.
-
(±)4-HDHA
(±)4-HDHA (4-Hydroxy docosahexaenoic acid) is a PPARγ agonist with anti-inflammatory activity that directly inhibits endothelial cell proliferation and sprouting angiogenesis via PPARγ, which can be used in the study of diabetes.
-
TCS 359
TCS 359 is a potent FLT3 inhibitor with IC50 of 42 nM.
